BioSpecifics Technologies announces FDA approval of sBLA for XIAFLEX®
BioSpecifics Technologies announced the FDA has approved the sBLA submitted by BioSpecifics' partner, Auxilium Pharmaceuticals, for XIAFLEX for treatment of up to two Dupuytren's contracture cords in the same hand during a single treatment visit. October 21, 2014